VAS3947

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526646

CAS#: 869853-70-3

Description: VAS3947 is a selective inhibitor of NADPH oxidase activity in low micromolar concentrations, interfering neither with ROS detection nor with XOD or eNOS activities.


Price and Availability

Size
Price

Size
Price

Size
Price

VAS3947 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 526646
Name: VAS3947
CAS#: 869853-70-3
Chemical Formula: C14H10N6OS
Exact Mass: 310.0637
Molecular Weight: 310.335
Elemental Analysis: C, 54.18; H, 3.25; N, 27.08; O, 5.16; S, 10.33


Synonym: VA-S3947; VA S3947; VAS3947

IUPAC/Chemical Name: 3-Benzyl-7-(2-oxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine

InChi Key: JVZDLDFNSCFLPM-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H10N6OS/c1-2-4-10(5-3-1)8-20-12-11(18-19-20)13(17-9-16-12)22-14-15-6-7-21-14/h1-7,9H,8H2

SMILES Code: C12=NC=NC(SC3=NC=CO3)=C1N=NN2CC4=CC=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Hecht N, Terveer N, Schollmayer C, Holzgrabe U, Meinel L. Opening NADPH oxidase inhibitors for in vivo translation. Eur J Pharm Biopharm. 2017 Jun;115:206-217. doi: 10.1016/j.ejpb.2017.03.001. Epub 2017 Mar 8. PubMed PMID: 28284727.

2: Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012. Epub 2012 Mar 3. Review. PubMed PMID: 22405985; PubMed Central PMCID: PMC3378316.

3: Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010 Oct;161(4):885-98. doi: 10.1111/j.1476-5381.2010.00920.x. PubMed PMID: 20860666; PubMed Central PMCID: PMC2970907.